Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05572398 · ClinicalTrials.gov registry record · NA
Online Bullying Bystander Intervention for Middle Schools Phase II
A NA study, sponsored by Klein Buendel.
- Completed
- Registry status
- NA
- Development phase
- 613
- Enrollment target
NCT05572398: Completed NA study, sponsored by Klein Buendel.
NCT05572398 is a NA study that has completed, run by Klein Buendel. The registered enrollment target is 613 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05572398, a NA study, has completed, sponsored by Klein Buendel.
- COMPLETED
- Registry status
- NA
- Development phase
- 613 participants
- Enrollment target
Study Summary
School interventions to reduce bullying can be effective but also require substantial time and resources. Online technologies have the potential to deliver effective bullying interventions to a large number of middle school students for less cost. The feasibility of delivering the effective STAC bullying intervention through a mobile web app will be tested using focus groups with middle school students and development and usability testing and the efficacy of the program will be tested using a randomized controlled trial.
Primary Outcome
An 11 item questionnaire measuring students' knowledge of buying, knowledge of the STAC-T strategies, and students' confidence to intervene in bullying situations. Items are rated on a 4-point Likert Scale ranging from 1 (Totally Disagree) to 4 (Totally Agree) and were summed to compute a total scale score. The minimum value is 11 and the maximum value is 44, and a higher score means a better outcome.
Interventions
- BEHAVIORAL STAC-T
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 613 participants |
| Start Date | 2022-05-26 |
| Est. Completion | 2024-11-18 |
| Phase | NA |
What the finished NCT05572398 record still lists
NCT05572398 is an interventional study that assigns participants to a tested intervention. The registered 613 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 1 intervention - of which STAC-T is the first listed.
NCT05572398 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05572398 about?
NCT05572398 is a clinical study titled "Online Bullying Bystander Intervention for Middle Schools Phase II". School interventions to reduce bullying can be effective but also require substantial time and resources. Online technologies have the potential to deliver effective bullying interventions to a large number of middle school students for less cost. The feasibility of delivering the effective STAC bul...
What is the current status of trial NCT05572398?
This trial is currently completed. It is a NA study. The enrollment target is 613 participants. The study started on 2022-05-26. Estimated completion is 2024-11-18.
What interventions are being tested in trial NCT05572398?
The interventions under investigation include: STAC-T (BEHAVIORAL).
Who is sponsoring clinical trial NCT05572398?
This trial is sponsored by Klein Buendel, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05572398's enrollment target sits among peer trials
613 161st of 2000 higher than 1,840 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01810913 · 613 participants · Phase 2
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
- NCT03821857 · 614 participants · Phase 4
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
- NCT05006716 · 614 participants · Phase 1
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
- NCT06170788 · 614 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI